Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
13 1월 2023 - 11:00PM
Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and
TSX-V: ACST), a late-stage, specialty pharma company advancing
three clinical stage drug candidates addressing rare and orphan
diseases, today announced Jan D’alvise, CEO, will present and host
one-on-one meetings with investors at the Sidoti January Virtual
Investor Conference, taking place on January 18-19, 2023.
The presentation will begin at 3:15pm ET on
Wednesday, January 18, 2023 and can be accessed live here:
https://sidoti.zoom.us/webinar/register/WN_xa9rpyXxTqOkjK89uESTug.
Acasti will also host virtual one-on-ones with investors on
Wednesday and Thursday, January 18-19, 2023. To register for the
presentation or one-on-ones, visit www.sidoti.com/events.
Registration is free and you don't need to be a Sidoti client.
About Acasti
Acasti is a specialty pharma company with drug
delivery technologies and drug candidates addressing rare and
orphan diseases. Acasti’s novel drug delivery technologies have the
potential to improve the performance of currently marketed drugs by
achieving faster onset of action, enhanced efficacy, reduced side
effects, and more convenient drug delivery—all which could help to
increase treatment compliance and improve patient outcomes.
Acasti’s three lead clinical assets have each
been granted Orphan Drug Designation by the FDA, which provides the
assets with seven years of marketing exclusivity post-launch in the
United States, and have additional intellectual property protection
with over 40 granted and pending patents. Acasti’s lead clinical
assets target underserved orphan diseases: (i) GTX-104, an
intravenous infusion targeting Subarachnoid Hemorrhage (SAH), a
rare and life-threatening medical emergency in which bleeding
occurs over the surface of the brain in the subarachnoid space
between the brain and skull; (ii) GTX-102, an oral mucosal spray
targeting Ataxia-telangiectasia (A-T), a progressive,
neurodegenerative genetic disease that primarily affects children,
causing severe disability, and for which no treatment currently
exists; and (iii) GTX-101, a topical spray targeting Postherpetic
Neuralgia (PHN), a persistent and often debilitating neuropathic
pain caused by nerve damage from the varicella zoster virus
(shingles), which may persist for months and even years. For more
information, please
visit: https://www.acastipharma.com/en.
Forward-Looking Statements
Statements in this press release that are not
statements of historical or current fact constitute
“forward-looking statements” within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995, as amended, Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and “forward-looking
information” within the meaning of Canadian securities laws
(collectively, “forward-looking statements”). Such forward looking
statements involve known and unknown risks, uncertainties, and
other unknown factors that could cause the actual results of Acasti
to be materially different from historical results or from any
future results expressed or implied by such forward-looking
statements. In addition to statements which explicitly describe
such risks and uncertainties, readers are urged to consider
statements containing the terms “believes,” “belief,” “expects,”
“intends,” “anticipates,” “estimates”, “potential,” “should,”
“may,” “will,” “plans,” “continue”, “targeted” or other similar
expressions to be uncertain and forward-looking. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press
release.
These forward-looking statements are based upon Acasti’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, including, without limitation: (i) the success and
timing of regulatory submissions of the planned Phase 3 safety
study for GTX-104 and Acasti’s other pre-clinical and clinical
trials; (ii) regulatory requirements or developments and the
outcome of meetings with the FDA; (iii) changes to clinical trial
designs and regulatory pathways; (iv) legislative, regulatory,
political and economic developments; and (v) costs associated with
Acasti’s clinical trials. The foregoing review of important factors
that could cause actual events to differ from expectations should
not be construed as exhaustive and should be read in conjunction
with statements that are included herein and elsewhere, including
the risk factors detailed in documents that have been and may be
filed by Acasti from time to time with the SEC. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Acasti undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made.
Neither NASDAQ, the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Acasti Contact:
Jan D’AlviseChief Executive OfficerTel:
450-686-4555Email:info@acastipharma.com www.acastipharma.com
Investor Relations:Robert BlumLytham Partners,
LLC602-889-9700ACST@lythampartners.com
Acasti Pharma (TSXV:ACST)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Acasti Pharma (TSXV:ACST)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024